SCYNEXIS Inc SCYX

BREXAFEMME - published User side effects

[GMA133]

Join me by taking your action by contacting SCYX Investor Relations.

 

Today, I emailed Irina of SCYX - Investor Relations & recommended that Marco Taglietti, M.D.  launch a positive, enthusiastic & aggressive PR campaign ASAP, using many BREXAFEMME user experiences with their side effects, etc. SCYX should also comment on serious side effects, especially if these type of reactions are the (unfortunate) result of very serious rVVR infections.

I attached the WebMD web link below regarding the revues by the cohort of 7 that used BREXAFEMME.

 

Irina thanked me & advised that she would forward my recommendations to SCYX executive management.

 

 GLTAL

 

 

https://www.webmd.com/drugs/drugreview-181690-brexafemme-oral

[dmacd]

The problem is Mario and Christine are spending with reckless abandon. We need a businessman to run the company not a doctor. Mario can raise money but it dilutes so value is not delivered. Burry will sell. I should too. I thought the sales would br much better for the spend. Horrible results.

[JonathanJSmith]

Yeah, I agree - worse sales than I had expected. They should get a pop however when they submit their supplemental NDA vis-a-vis rVVC in Q2. I'm still holding as their MC is hovering around cash on hand. BTW, Burry sold his position a while ago. Cheers and good luck, JJ

[dmacd]

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend. Probably trading at 70% current cash with an approved blockbuster drug in sales mode. New cash is either due to slow sales ramp or accelerated new programs. Management does not care about the SP which means retail will get fleeced more but I am hopeful this might be the

[JonathanJSmith]

I'm disgusted too. What does $45MM get them, another quarter's worth of financing - maybe two? One would think that they'd do a financing AFTER their sNDA submittal. I guess they successfully managed to get their buddies on board, on the cheap. You're right, it's another fleecing of retail investors; it makes me wonder whether I'll waste my time with biotechs in the future